FCGR2A and agammaglobulinemia: This clinical diversity is likely driven by specific underlying genetic defects, as for example Bruton’s tyrosine kinase (defective in some forms of agammaglobulinemia) drives FcγR-mediated cytokine production in monocytes (17, 18).